drugset / Trial / NCT05070403
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
Phase 2
Active not recruiting
35 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Boehringer Ingelheim · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to find out if Afatinib can help treat participants with advanced cSCC.
Timeline
- Start
- 2021-10-01
- Primary completion
- 2027-02
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Afatinib | Small molecule | 40 mg | — |